Extension Study of Carvedilol RCT Study

Status Recruiting

Clinical Trial Summary

Patients who have completed 2-years treatment in RCT Study of carvedilol will receive another 2-years extension therapy, aiming to investigate the long-term efficacy of carvedilol for the prevention of esophageal varices in treated HBV cirrhotic patients.

Clinical Trial Description

Carvedilol has been shown to be more potent in decreasing portal hypertension than propranolol. But the efficacy of carvedilol to prevent esophageal varices progression in nucleoside analogue (NUCs) treatment HBV related cirrhotic patients was unclear. Previous RCT study aimed to explore the effects of carvedilol for the prevention of the esophageal varices progression on HBV cirrhotic patients with anti-viral therapy has been conducted (NCT03736265). Patients who have completed 2-years treatment in RCT Study of carvedilol will receive another 2-years extension therapy, aiming to investigate the long-term efficacy of carvedilol for the prevention of esophageal varices in treated HBV cirrhotic patients. Patients were allocated according to the outcome of EDGs at 2-year during RCT study. Patients will be assessed at baseline and every six months for blood cell count, liver function test, HBVDNA, AFP, prothrombin time, liver ultrasonography, and Fibroscan. A third EGDs will be performed at 4-year. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05021406
Study type	Interventional
Source	Beijing Friendship Hospital
Contact	Xiaojuan Ou, Dr
Phone	+86-010-63138665
Email	ouxj16@126.com
Status	Recruiting
Phase	N/A
Start date	January 8, 2021
Completion date	October 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04533932` - Endosonographic Shear Wave Elastography for Liver Stiffness
Not yet recruiting	`NCT06031740` - A Comparison of Flexible Endoscopic Polidocanol Liquid and Foam Sclerotherapy in Cirrhotic Patients With Bleeding From Internal Hemorrhoids	N/A
Not yet recruiting	`NCT06026267` - Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis	N/A
Not yet recruiting	`NCT06076330` - Efficacy of 5% Albumin v/s Plasmalyte in Combination With 20% Albumin for Fluid Resuscitation in Cirrhosis With Sepsis Induced Hypotension	N/A
Enrolling by invitation	`NCT05055713` - A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism	N/A
Recruiting	`NCT04578301` - Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
Not yet recruiting	`NCT05515861` - Evaluation of EUS in Preventing Rebleeding After Endoscopic Cyanoacrylate Injection for Gastric Varices	N/A
Not yet recruiting	`NCT05120557` - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH	N/A
Not yet recruiting	`NCT02710227` - Sleep Timing and Circadian Preferences in A Sample of Egyptian Patients With Hepatic Cirrhosis	N/A
Not yet recruiting	`NCT03623360` - Functional MRI to Determine Severity of Cirrhosis
Completed	`NCT02917408` - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Active, not recruiting	`NCT02551250` - Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis
Recruiting	`NCT02239991` - Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant	N/A
Enrolling by invitation	`NCT02256514` - Open Label Trial of Immunotherapy for Advanced Liver Cancer	Phase 2
Terminated	`NCT02311985` - Comparison of Three Transfusion Strategies for Central Venous Catheterization in Cirrhotics: A Randomized Clinical Trial	N/A
Terminated	`NCT01937130` - Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF	Phase 2
Recruiting	`NCT01724697` - Safety and Efficacy of Human Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis	Phase 1/Phase 2
Recruiting	`NCT01728688` - Safety and Efficacy of Human Autologous Peripheral Blood Stem Cells for Treatment of HBV-related Liver Cirrhosis	Phase 1/Phase 2
Recruiting	`NCT01728727` - Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis	Phase 1/Phase 2
Recruiting	`NCT01618890` - Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding	Phase 3